Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ: FLGT )

16.90 +0.04 (+0.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
Fulgent is moving past its pandemic-era business, and that's a good thing. 
Via The Motley Fool
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
From Fulgent Genetics, Inc.
Via Business Wire
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both. 
Via The Motley Fool
Fulgent Genetics Earnings Perspective: Return On Capital Employed
Via Benzinga
Fulgent Genetics: Q1 Earnings Insights
Via Benzinga
Preview: Fulgent Genetics's Earnings
Via Benzinga
Looking Into Fulgent Genetics's Return On Capital Employed
Via Benzinga
Where Fulgent Genetics Stands With Analysts
Via Benzinga
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales. 
Via The Motley Fool
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Fulgent Reports First Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Fulgent Genetics's Return on Invested Capital Insights
Via Benzinga
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion. 
Via Benzinga
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
From Fulgent Genetics, Inc.
Via Business Wire
7 Stocks to Buy to Bag Big-Time Returns in Q2
If you’re willing to take huge risks, these stocks to buy might yield you massive gains in Q2 – or you could be looking at a tax write-off. 
Via InvestorPlace
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
From Fulgent, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
From Fulgent Genetics, Inc.
Via Business Wire
NASDAQ:FLGT Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulgent Genetics, Inc.
San Diego, CA -- (SBWIRE) -- 02/09/2023 -- An investigation was announced for current long-term investors in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) concerning potential breaches of fiduciary... 
Via SBWire
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday's trading, 71 companies set new 52-week lows. 
Via Benzinga
Fulgent Expands Board of Directors with Addition of Reggie Groves
From Fulgent Genetics, Inc.
Via Business Wire
Which Is the Better Buy: Vertex or Invitae?
Is Vertex worth its lofty valuation compared to Invitae? 
Via The Motley Fool
My Top 7 Strong Conviction Buys for 2023
Companies that are down on their luck this year are in strong contention for conviction buys for 2023 as they rebound. 
Via InvestorPlace
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT
From Scott+Scott Attorneys at Law LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.